secwatch.observer — SEC 8-K summary
======================================

Issuer:     LEXICON PHARMACEUTICALS, INC. (LXRX)
CIK:        0001062822
Form:       8-K
Filed at:   2024-09-16T23:59:59+00:00
Accession:  0001062822-24-000051
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lexicon Pharma CFO/COO Jeffrey Wade to depart Sep 30; Kristen Alexander named principal financial officer
--------------------------------------------------------------------------------

- Jeffrey Wade's employment as president, COO and principal financial officer terminates Sep 30, 2024.
- Wade receives salary continuation of $585k for 12 months, lump sum $175.5k, COBRA $3.7k/mo for 12 months, plus outplacement.
- Wade enters 8-month consulting agreement at $3,000/month starting after termination.
- Kristen Alexander, VP finance and accounting and principal accounting officer since 2021, becomes principal financial officer.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/0001062822-24-000051-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1062822/000106282224000051/lxrx-20240913.htm
  HTML page:      https://secwatch.observer/filing/0001062822-24-000051

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer